Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report
verfasst von:
Ibrahim O. Ahmed, Lauretta O. Ochogwu, Temilola O. Owojuyigbe, Norah O. Akinola, Muheez A. Durosinmi
The occurrence of acute leukemia in patients with sickle cell anemia is uncommon. The Philadelphia chromosome is the hallmark of chronic myeloid leukemia. However, it may also be associated with acute lymphoblastic leukemia and acute myeloblastic leukemia. The common BCR-ABL1 transcripts seen in acute lymphoblastic leukemia are e1a2, e13a2, and e14a2, while other transcripts such as e1a3, e13a3, and e6a2 occur rarely. This report describes the presentation, management, and outcome of the occurrence of B-cell acute lymphoblastic leukemia with the rare e1a3 BCR-ABL1 transcript in a patient with sickle cell anemia.
Case presentation
A 19-year-old male Nigerian, a known sickle cell anemia patient was admitted on account of severe vaso-occlusive crisis. Examination revealed fever, palor, and jaundice. Full blood count showed anemia and leukocytosis. Peripheral blood and bone marrow smears revealed numerous large and small lymphoblasts in keeping with the L2 subtype of acute lymphoblastic leukemia based on the French–American–British classification. Further evaluation was in keeping with a diagnosis of BCR-ABL1-positive mature B-cell acute lymphoblastic leukemia associated with the rare e1a3 transcript. He was commenced simultaneously on induction chemotherapy and Imatinib while being prepared for allogeneic stem cell transplantation. However, he died six months after diagnosis from meningoencephalitis.
Conclusion
The occurrence of acute lymphoblastic leukemia with a rare BCR-ABL1 e1a3 transcript in association with sickle cell anemia is uncommon and associated with poor prognosis.
Hinweise
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ALL
Acute lymphoblastic leukemia
AML
Acute myeloblastic leukemia
CCR
Complete cytogenetic remission
CD
Cluster of differentiation
CML
Chronic myeloid leukemia
CMML
Chronic myelomonocytic leukemia
CNS
Central nervous system
CSF
Cerebrospinal fluid
ECG
Electrocardiogram
ECHO
Echocardiogram
FAB
French–American–British (classification)
FBC
Full blood count
GCS
Glasgow Coma Scale
G-CSF
Granulocyte colony stimulating factor
GMALL
German Multicenter ALL (study group)
Hb
Hemoglobin
HIV
Human immunodeficiency virus
HLA
Human leukocyte antigen
HSCT
Hemopoietic stem cell transplantation
ICU
Intensive care unit
ICP
Intracranial pressure
IT
Intrathecal therapy
NCI
National Cancer Institute, Bethesda
PCR
Polymerase chain reaction
RBC
Red blood cell
SCA
Sickle cell anemia
SCD
Sickle cell disease
TKI
Tyrosine kinase inhibitor
USA
United States of America
WBC
White blood cell
WIA
Cancer Institute, Chennai, India
Introduction
Sickle cell anemia (SCA) is the most prevalent hemoglobinopathy worldwide and occurs due to the homozygous inheritance of hemoglobin S (HbS) [1]. Hemoglobin S is an abnormal form of adult hemoglobin (HbA) that is produced due to a point mutation in the sixth codon of the beta globin gene (GAG to GTG) resulting in the replacement of the hydrophilic amino acid glutamate by the hydrophobic amino acid valine in the sixth position of the Hb beta chain. The abnormal HbS polymerizes when deoxygenated and induces sickling of red blood cells (RBCs). The clinical features include chronic hemolysis, anemia, and periodic episodes of acute pain termed vaso-occlusive crisis (VOC) [2]. The occurrence of acute leukemia in individuals with SCA is rare [2, 3]. This has been attributed to the reduced life expectancy associated with SCA. The Philadelphia chromosome (Ph) is the shortened chromosome 22 that results from the reciprocal translocation between the long arms of chromosomes 9 and 22, that is, (t9;22)(q34:q11) with the formation of a novel fusion gene BCR-ABL1 that drives oncogenesis due to increased tyrosine kinase activity [4]. This acquired gene rearrangement is most classically associated with CML, but it could also be found in ALL and AML [4, 5]. There are many variants of the BCR-ABL1 fusion gene depending on the site of breakpoint in the BCR gene [5]. The most common BCR-ABL1 fusion transcript seen in about 70% of Ph-positive ALL is the p190 variant, which results from the rearrangement between exon 1 of BCR and exon 2 of ABL1, that is, e1a2. About 30% of cases of Ph-positive ALL are associated with the p210 variant [that has two forms, namely e13a2 (or b2a2) and e14a2 (or b3a2)] [6]. Baccaranni et al., however, reported the occurrence of e13a2 transcript in 58.5% of 497 BCR-ABL1 positive ALL patients [7]. Atypical variants of the BCR-ABL1 gene such as e1a3, e13a3, and e6a2 occur rarely [6, 8]. The presence of BCR-ABL1 transcript in ALL is associated with a relatively poor prognosis, necessitating the addition of tyrosine kinase inhibitor (TKI) into the treatment regimen [7].
Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia is a distinct entity that is characterized by specific genomic alterations, low sensitivity to chemotherapy, unstable responsiveness to tyrosine kinase inhibitors (TKIs), and a poor prognosis [8, 9].
Anzeige
We report a rare case of Ph-positive B-cell ALL with e1a3 BCR-ABL1 transcript in a 19-year-old Nigerian with SCA.
Case presentation
A 19-year-old Nigerian, known SCA patient who was diagnosed in childhood but had been receiving care in a secondary health facility presented to the emergency room in May 2020 with generalized body pains, fever, weakness, and palpitations of four days duration. There was no history of passage of dark-colored urine, thus excluding hemolysis. The patient had never used hydroxycarbamide nor any other disease-modifying agent. He was diagnosed to have SCA at the age of 1 year during a febrile illness when a routine Hb electrophoresis was done. In early childhood, he had frequent episodes of VOC that required hospitalization (more than four times annually) and required numerous blood transfusions (more than three times in a year). However, in his teenage years, VOCs were said to have become less frequent (once or twice in a year) and less intense with significant reduction in hospital admission rate (once or twice in a year) and blood transfusion requirements (less than once in a year). The last episode of crises that required hospitalization (at a private hospital in Port-Harcourt, Nigeria) occurred a year prior to index presentation. The last blood transfusion was at age 15 years. He did not attend any clinic for follow-up, but presented mainly at the emergency room during crises when home treatment was not effective. He did not have splenectomy as this is not routinely done in Nigeria for patients with SCA. He was not compliant with the prescribed daily medications, which included proguanil, folic acid, vitamin B-complex, and vitamin C. He was the last of three children in a monogamous family, in which both parents and his siblings had Hb AS phenotype.
High risk: Start at 100 mg/m2 and increase by 50 mg/m2 up to 5 doses
CNS prophylaxis as in Induction 1A
IT day 8, 15, 22, 29
Induction 1B
28 days
Repeat Induction 1A
As in Induction 1A
Consolidation
28 days
Cytarabine
Vincristine
Cyclophosphamide
Daunorubicin
6-Mercaptopurine
100 mg/m2; SC 12-hourly day 1–3, 15–17
1.4 mg/m2; IV day 1, 15
750 mg/m2; IV day 1
20 mg/m2; IV day 15
75 mg/m2; PO day 1–7, 15–21
CNS prophylaxis:- Drugs as in Induction 1A
IT day 1
Maintenance
8 cycles for B-ALL (12 weeks per cycle)
96 weeks
Prednisolone
Vincristine
Daunorubicin
l-Asparaginase
6-Mercaptopurine
Methotrexate
40 g/m2; PO day 1–7
1.4 mg/m2; IV day 1
20 mg/m2; IV day 1
6000 U/m2; SC day 1, 3, 5, 7
75 mg/m2; PO daily × 12 doses
15 mg/m2; PO weekly
CNS prophylaxis:- Methotrexate
12 mg; IT day 1 of each cycle
×
×
Discussion
The life expectancy of patients with SCA has improved in recent years owing to advances in management that may be associated with the many cases of malignancies now being reported in these patients. In Nigeria, 8.6% of cases of acute leukemia were associated with sickle cell disease, among which there was only one case of ALL [2]. Brunson et al. found an increased risk of leukemia in patients with SCD when compared with the general population [12]. The factors associated with this increased risk include chronic inflammation, increased iron levels from frequent transfusions, increased risk of infections, increased erythroid proliferation, and increased bone marrow turnover, which form the pathophysiologic mechanisms of the clinical manifestations of SCD [12]. The index patient presented with typical clinical features of VOC and severe anemia, which occur commonly in patients with SCA. The detection of lymphoblasts in the peripheral blood smear provided the clue to the diagnosis of ALL, which was confirmed by further investigations such as BMA, BCR-ABL1 analysis by PCR, and the immunophenotype. The clinical phenotype of SCA in the patient had been severe with frequent episodes of VOCs and blood transfusions, which were said to have become ameliorated in his teenage years. The ECG and echocardiographic findings of LVH were consistent with chronic anemia, which also occurs frequently in patients with SCA [13].
Anzeige
The BCR-ABL1 fusion gene results from the reciprocal translocation between the long arms of chromosomes 9 and 22, that is, t(9;22)(q34;q11) [4]. The ABL1 tyrosine kinase gene is transferred from its normal position on chromosome 9 to a new position beside the BCR gene on chromosome 22, resulting in the generation of a novel, highly oncogenic fusion gene (BCR-ABL1) with a very high constitutive tyrosine kinase activity. This BCR-ABL1 gene is expressed in 95% of patients with CML, 25–30% of adult ALL, and 2–3% of ALL in children [5, 14, 15]. The most common BCR-ABL1 rearrangement in ALL is the e1a2 transcript with a molecular weight of 190 kDa (that is, p190), but the e13a2 (or b2a2) and e14a2 (or b3a2) transcript variants occur less frequently [16]. Other variants such as the e1a3 as reported in this index case are rarely seen in ALL, resulting from the translocation between exon 1 of BCR on chromosome 22 and exon 3 of ABL1 on chromosome 9 [15]. The exon 2 (a2) region of ABL1 that encodes a part of the Src homology (SH) 3 domain is missing from the e1a3 BCR-ABL1 transcript. The role of the SH3 domain in leukemogenesis is controversial. It is a negative regulator of the kinase domain (SH1) of ABL1 and BCR-ABL1 [15]. Therefore, the absence or mutation of the SH3 domain may be associated with a more aggressive form of Ph-positive leukemia due to the loss of its autoinhibitory effect on kinase activity. On the other hand, the SH3 domain is also required for STAT5 activation by the BCR–ABL1 protein, which is necessary for the expression of its full leukemogenetic effect. In this instance, mutation of SH3 domain could be associated with a slowly progressive disease. In CML with the e1a3 transcript, the lack of the SH3 domain was associated with inferior response to Imatinib when compared with the major transcripts and rapid progression to blastic crisis [17]. In other CML patients, the e1a3 transcript was associated with better outcomes [14, 16, 18, 19].
The clinical profile of e1a3 is expected to be similar to that of e1a2 because of their identical molecular weight (190kDa). However, in CML, the e1a2 transcript is associated with monocytosis, extramedullary infiltration, and rapid disease progression similar to chronic myelomonocytic leukemia (CMML) [19].
The MCP 841 chemotherapy protocol is a multiagent, multiphase, moderate-intensity regimen that was developed through a collaboration between the Cancer Institute (WIA), Chennai, India and the National Cancer Institute (NCI), Bethesda, USA. It is a standardized treatment protocol that has led to improved survival rates and reduction in treatment-related toxicity among pediatric and adolescent ALL patients treated in resource-poor settings. In the MCP 841 protocol, CNS prophylaxis involves IT alone (in patients younger than 3 years of age) or with cranial irradiation (in patients older than 3 years of age) [10, 11]. Cranial irradiation is effective, but frequently complicated by significant short-term and long-term toxicity, such as, neurocognitive dysfunction, endocrinopathy, secondary neoplasms, and neurotoxicity [23]. Studies have shown that cranial irradiation can be safely omitted from CNS prophylaxis even in high-risk adult or pediatric patients by means of effective systemic chemotherapy and intensive triple intrathecal therapy [24‐26]. The protocol modification used in this case involved the replacement of cranial irradiation with the Capizzi escalating-dose systemic methotrexate and triple IT for CNS prophylaxis [26, 27], because there are no facilities for cranial irradiation in our center.
There are relatively few studies on the significance of BCR-ABL1 transcript types in ALL. Some reports have described the presence of the e1a3 transcript in ALL; however, to the best of our knowledge, this is the first report of such in a patient with SCA [28, 29]. In addition, this is the first report from Nigeria in which cytogenetic and immunophenotype analyses were done in the diagnosis of acute leukemia in any patient with SCD. There is limited utilization of cytogenetics and flow cytometry in the diagnostic workup of acute leukemia patients in Nigeria owing to lack of facilities in most centers [2, 3].
Fujisawa et al. reported e1a3 transcript in a 25-year old female with precursor B-ALL who presented with leukocytosis and thrombocytopenia. Similar to this index case, the patient had chemotherapy and Imatinib therapy simultaneously and achieved complete remission after the first induction cycle. However, the patient succumbed to veno-occlusive disease 18 months from the date of diagnosis [30]. Similarly, Langerbeer et al. reported this rare transcript in a 62-year-old female with Pre-B ALL who also had concomitant chemotherapy with Imatinib therapy. The patient achieved remission with fludarabine, cytarabine, G-CSF, and idarubicin, but relapsed at 18 months and died at 27 months [28]. Lopez-Andrade et al. reported two patients ALL with the e1a3 BCR-ABL1 ALL transcript. In both patients, the BCR-ABL1 transcript remained detectable after induction chemotherapy despite the addition of Imatinib. The first patient achieved complete response by morphology and immunophenotype. The second patient did not respond to treatment based on the presence of lymphoblasts in the post-induction BMA and persistence of BCR-ABL1; he died after second-line induction due to gastrointestinal bleeding [31].
Burmeister et al. of the German Multicenter ALL (GMALL) Study Group detected BCR-ABL1 transcripts in 34% of 1214 adult B-precursor ALL cases. Eight of these patients had atypical transcripts, five of which were e1a3, two e13a3, and one e6a2 [6].
In all the previously reported cases, the patients died between nine and 27 months unlike this index patient, who died within six months of diagnosis. The shorter duration of survival reported in this case might be due to the associated comorbidities, namely the SCA and meningoencephalitis, which complicated the treatment. Infections are commonly implicated as contributory factors to mortality in ALL patients. In the index patient, an increased risk of severe infection could be linked to impaired cellular and humoral immunity from the cumulative effects of SCA, ALL, and cancer chemotherapy [32].
Anzeige
Nigeria is located within the “meningitis belt” in Sub-Saharan Africa, and outbreaks of meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae occur frequently [33]. Methicillin-resistant Staphylococcal aureus could also be a cause in the patient considering the history of previous soft-tissue infection caused by the organism in him. In immunocompromised individuals, meningitis could be caused by atypical organisms such as Listeria monocytogenes, Cryptococcus neoformans, Acanthamoeba species, or herpes simplex virus [34]. The other differential diagnoses of meningoencephalitis in the patient include leukemic meningitis, aseptic meningitis, and drug-induced meningitis (from IT therapy) [35].
While numerous variant BCR-ABL1 transcripts and their responses to a variety of treatment modalities have been documented in CML [15, 17, 36]. There are fewer reports on these rare variants in Ph+ ALL: the largest series examined to date reveals a total incidence of 1.9%, with the e1a3 transcript type being the most frequently detected at about 1.2% [6]. All the patients had induction therapy with or without Imatinib. The patients who were treated with Imatinib had better survival after HSCT and less risk of relapse than those who were not treated with Imatinib. The time to HSCT ranged from 100 to 180 days after diagnosis [6]. The index patient died before HSCT could be done on day 180.
Conclusion
The occurrence of ALL with the rare e1a3 BCR-ABL1 transcript in SCA is associated with poor prognosis. There is need to develop standardized treatment protocols to improve survival. Stem cell transplantation should be made available to patients as early as possible to improve survival. Routine examination of the peripheral blood film of patients with SCA presenting with features of crises is recommended. Molecular techniques should be included in the diagnostic workup of patients with acute leukemia.
Acknowledgements
The authors would like to thank all staff of the Department of Haematology and Blood Transfusion, Obafemi Awolowo University Teaching Hospitals Complex for their assistance and the patient’s relatives for their cooperation. The authors acknowledge The Max Foundation for facilitating the free provision of Imatinib to Nigerian patients since 2003.
Anzeige
Declarations
Ethics approval and consent to participate
Ethical approval was obtained from the Ethics and Research Committee of Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Nigeria.
Consent for publication
Written informed consent was obtained from the patient’s next-of-kinfor publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.
Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report
verfasst von
Ibrahim O. Ahmed Lauretta O. Ochogwu Temilola O. Owojuyigbe Norah O. Akinola Muheez A. Durosinmi